company background image
CMRX

ChimerixNasdaqGM:CMRX Stock Report

Market Cap

US$490.8m

7D

-4.2%

1Y

56.1%

Updated

04 Dec, 2021

Data

Company Financials +
CMRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CMRX Stock Overview

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases.

Chimerix Competitors

Emergent BioSolutions

NYSE:EBS

US$2.3b

Celldex Therapeutics

NasdaqCM:CLDX

US$1.7b

Novartis

SWX:NOVN

CHF164.6b

GlaxoSmithKline

LSE:GSK

UK£76.9b

Price History & Performance

Summary of all time highs, changes and price drops for Chimerix
Historical stock prices
Current Share PriceUS$5.65
52 Week HighUS$11.57
52 Week LowUS$3.41
Beta1.44
1 Month Change-3.91%
3 Month Change-18.00%
1 Year Change56.08%
3 Year Change71.73%
5 Year Change9.28%
Change since IPO-69.93%

Recent News & Updates

Sep 16
Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Jun 08
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

CMRXUS BiotechsUS Market
7D-4.2%-4.1%-2.7%
1Y56.1%-1.4%16.6%

Return vs Industry: CMRX exceeded the US Biotechs industry which returned 1.8% over the past year.

Return vs Market: CMRX exceeded the US Market which returned 19.4% over the past year.

Price Volatility

Is CMRX's price volatile compared to industry and market?
CMRX volatility
CMRX Average Weekly Movement8.0%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: CMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CMRX's weekly volatility has decreased from 13% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200054Mike Shermanhttps://www.chimerix.com

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications.

Chimerix Fundamentals Summary

How do Chimerix's earnings and revenue compare to its market cap?
CMRX fundamental statistics
Market CapUS$490.77m
Earnings (TTM)-US$145.41m
Revenue (TTM)US$3.05m

160.8x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CMRX income statement (TTM)
RevenueUS$3.05m
Cost of RevenueUS$48.17m
Gross Profit-US$45.11m
ExpensesUS$100.30m
Earnings-US$145.41m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.67
Gross Margin-1,477.69%
Net Profit Margin-4,762.95%
Debt/Equity Ratio13.4%

How did CMRX perform over the long term?

See historical performance and comparison

Valuation

Is Chimerix undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CMRX ($5.65) is trading below our estimate of fair value ($101.73)

Significantly Below Fair Value: CMRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CMRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CMRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CMRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CMRX is overvalued based on its PB Ratio (4.7x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is Chimerix forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

68.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CMRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CMRX's is expected to become profitable in the next 3 years.

Revenue vs Market: CMRX's revenue (51.6% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: CMRX's revenue (51.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CMRX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Chimerix performed over the past 5 years?

-9.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CMRX is currently unprofitable.

Growing Profit Margin: CMRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CMRX is unprofitable, and losses have increased over the past 5 years at a rate of 9.9% per year.

Accelerating Growth: Unable to compare CMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: CMRX has a negative Return on Equity (-139.04%), as it is currently unprofitable.


Financial Health

How is Chimerix's financial position?


Financial Position Analysis

Short Term Liabilities: CMRX's short term assets ($128.5M) exceed its short term liabilities ($26.3M).

Long Term Liabilities: CMRX's short term assets ($128.5M) exceed its long term liabilities ($2.5M).


Debt to Equity History and Analysis

Debt Level: CMRX has more cash than its total debt.

Reducing Debt: CMRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CMRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CMRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Chimerix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CMRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CMRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CMRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Mike Sherman (55 yo)

2.67yrs

Tenure

US$2,103,428

Compensation

Mr. Michael A. Sherman, also known as Mike, serves as Director at Werewolf Therapeutics, Inc. since May 2021. He has Over 30 years of experience in advancing therapeutics to commercial launch and driving c...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD2.10M) is about average for companies of similar size in the US market ($USD1.76M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CMRX's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: CMRX's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CMRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.7%.


Top Shareholders

Company Information

Chimerix, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Chimerix, Inc.
  • Ticker: CMRX
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$490.773m
  • Shares outstanding: 86.86m
  • Website: https://www.chimerix.com

Number of Employees


Location

  • Chimerix, Inc.
  • 2505 Meridian Parkway
  • Suite 100
  • Durham
  • North Carolina
  • 27713
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 00:03
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.